Xalud TherapeuticsXalud Therapeutics
  • Home
  • The Science We’re Exploring
    • Basic Overview
    • Non-Clinical Results
  • Pipeline
  • About Xalud
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Media
  • Contact us
  • No menu assigned!
Feb 08 2013
0

Xalud Therapeutics Announces Award of $690,000 Grant from the NIH to Study Multiple Sclerosis

By xalud-admin | Press Release | No Comments

SAN FRANCISCO, California. February 8, 2013 – Xalud Therapeutics, Inc., a private biotechnology company, announced that it had been awarded a $690,000 SBIR grant from the National Institute of Neurological Disorders and Stroke, a division of the National Institutes of Health. The grant, which will be paid over…

Read More
Jun 02 2010
0

American, Israeli biochemists win Spanish Asturias prize for their work on pain

By xalud-admin | Uncategorized | No Comments

MADRID –  MADRID (AP) — Two American biochemists and another from Israel were awarded one of Spain’s Prince of Asturias awards Wednesday for their research into the workings of pain. The Prince of Asturias Foundation said Americans David Julius and Linda Watkins and Israel’s Baruch Minke were granted the 2010…

Read More
« Previous Entries

Recent Posts

  • PBM Capital Group Invests in Xalud Therapeutics
  • Targeting Glia to Treat Chronic Pain, Linda Watkins PhD, Kreshover Lecture
  • Breakthrough gene therapy relieves chronic pain in dogs
  • Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East
  • Xalud Supports Study of XT-101 in Pet Dogs with Osteoarthritis

About Xalud

Xalud Therapeutics, Inc. is developing novel therapies for the treatment of neuro-inflammatory diseases. Xalud is also developing treatments for inflammatory joint disorders including osteoarthritis and rheumatoid arthritis.

Recent Posts

  • PBM Capital Group Invests in Xalud Therapeutics June 25, 2015
  • Targeting Glia to Treat Chronic Pain, Linda Watkins PhD, Kreshover Lecture May 5, 2015
  • Breakthrough gene therapy relieves chronic pain in dogs September 26, 2013
  • Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East July 11, 2013
  • Xalud Supports Study of XT-101 in Pet Dogs with Osteoarthritis June 24, 2013

Contact Us

Xalud welcomes inquiries regarding development partnerships, investment and scientific collaboration. Please contact us if you are interested in learning more about Xalud. We look forward to speaking with you.
 
Contact Us

© 2019 Xalud Therapeutics. All rights reserved. | Privacy Statement

  • Home
  • The Science We’re Exploring
    • Basic Overview
    • Non-Clinical Results
  • Pipeline
  • About Xalud
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Media
  • Contact us